Gilead COVID-19 drug may exceed $2 billion sales, analysts say
NEW YORK — At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.'s new medicine, could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler. That's the ...
from Google Alert - Business https://ift.tt/2SCpTYN
NEW YORK — At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.'s new medicine, could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler. That's the ... https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/2SCpTYN
NEW YORK — At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.'s new medicine, could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler. That's the ... https://ift.tt/eA8V8J
Comments
Post a Comment